Editor’s note: This opinion reflects the author’s analysis of potential market outcomes. The regulatory, commercial, and consumer shifts discussed remain contingent on future agency action, implementation, legislation, and market adoption.
Every operator I know spent April 28 watching the Drug Enforcement Administration. They were watching the wrong thing. The rescheduling order that took effect that day did not build the highway for pharmaceutical THC. The highway was already poured. Rescheduling just painted the lines.
What is coming over the next three years is not one rule. It is a convergence — several forces arriving at once — and when they meet they will split this market into two economies and move a wall of demand from one into the other. The operators who read the split early will own the next cycle.
Five things I expect, and none of them are waiting for permission.
1. A limited pharmaceutical THC channel already exists
A fully legal, fully national distribution system for pharmaceutical THC is running right now, and it owes nothing to rescheduling. Dronabinol, a Food and Drug Administration-approved form of synthetic THC, can be prescribed nationwide by telehealth today. It carries its own U.S. Pharmacopeia monograph, which means the molecule is defined by chemistry, not by origin. Synthesize it or pull it from the plant. If it meets the monograph, it qualifies.
Dronabinol shows that a federally regulated THC medicine is not theoretical. What rescheduling changed is the possibility that additional cannabis-derived products and qualifying state-licensed medical products may enter more formal federal channels.
Good Manufacturing Practice-grade material already ships at scale from makers like Benuvia, with a Drug Master File sitting at FDA. Compounding pharmacies already turn that material into patient prescriptions. Marinol, a dronabinol drug developed by AbbVie, bears a narrow label, cleared only for chemotherapy nausea and AIDS-related wasting. That has never mattered much, because physicians write off-label prescriptions every day; one in five prescriptions in the United States is off-label, according to the Agency for Healthcare Research. That is how gabapentin and trazodone became giants. The same door has been standing open for THC ever since the FDA approved dronabinol.
2. Cannabis crosses the U.S. border legally for the first time
April’s rescheduling order did something no cannabis policy before ever did: It placed marijuana drug products and state-licensed medical marijuana on the Schedule III import and export list. A single cannabis-derived drug had crossed under research permits before. This is a standing commercial pathway, and that is new.
Every country that spent the past decade building medical cannabis for export — Israel, Colombia, Canada, the Netherlands — now has a legal door into the largest market on earth. The first permits will move FDA-approved products and Active Pharmaceutical Ingredients. State-licensed material is likely to follow as the frameworks catch up. But the wall around American cannabis was the last one standing, and it just grew a gate. Once foreign material lands cheaper than domestic material, the pressure runs in only one direction.
3. Medical authorizations force a reckoning inside every federal institution
As access widens, the institutions that run on federal money will have to pick a side. Airports, federal buildings, hospitals that accept Medicare and Medicaid, public schools, transit systems. Each will meet patients holding valid authorizations and there will be no policy to greet them.
The courts already closed the employment question, ruling medical marijuana use is not protected under the Americans with Disabilities Act. The Department of Transportation (DOT) and the Transportation Safety Administration (TSA) split, with DOT maintaining a strict, zero-tolerance policy for marijuana use by safety-sensitive workers while TSA relaxed its rules about medical cannabis in checked and carry-on luggage.
The fight will move into constructing rules next, fought one lobby and one human-resources manual at a time over the next two to three years.
4. Neighborhood pharmacies dispense THC within three years
Inside that three-year window, large pharmacy chains will become a more visible dispensing channel for FDA-approved or otherwise federally compliant THC medicines. Marinol and other dronabinol formulations will ride the same pipes as everything else in the building. Compounded versions will reach patients through specialty networks. The apparatus is already built and waiting: monographs, GMP supply, Schedule III handling, specialty pharmacy, telehealth prescribing.
Flower and edibles will not make this trip. They will stay in dispensaries under state regulation. What will move through the pharmacy chain is the molecule, clean and dosed and one reimbursement decision away from mainstream. The paradigm will arrive before the cannabis industry is ready.
5. The hemp collapse hits retail before pharma does
On November 12, 2026, the federal definition of hemp will narrow, and the intoxicating hemp market that colonized gas stations and smoke shops all over the country will lose its legal ground. At the same moment, rescheduling may pull legitimate THC toward licensed and pharmaceutical channels. Put those together and a wall of displaced demand goes looking for a new home. Some of it will disappear. Most consumers, though, will walk into licensed dispensaries because that will be their only option.
There are bills in both chambers of Congress to delay or repeal the intoxicating hemp ban, but the tide of change will not depend on the date. The unregulated channel is closing. The licensed shelf is where that demand has to go. Operators with real production capacity are about to inherit a new customer base.
Who actually moves, and who doesn’t
Legality builds the channel. Incentives fill it. And the patient who walks into the pharmaceutical channel is, for the most part, not your Friday-night beverage customer. Many of them have never set foot in a dispensary and never will: the 67-year-old who is managing chronic pain, the veteran inside the Veterans Administration system, the nurse in a safety-sensitive job whose employer can live with a prescription but not a dispensary receipt, the patient who crosses state lines and needs the medicine to travel with them, the one whose doctor will write a script but will never recommend a gummy he cannot dose.
Add insurance reimbursement, whenever it lands, and the whole thing accelerates. The pharmaceutical channel reaches a population dispensaries weren’t built to serve. Different patients, different doors, almost no overlap.
Reading the seam
Step back, and the next cycle is not hard to imagine: two economies, side by side. One pharmaceutical, built on a defined molecule, GMP supply, scripts, specialty networks, and imports. The other experiential, built on flower and edibles and cannabis beverages and the simple ritual of walking into a store. They run on separate rails toward separate customers, and the operator who braces for the pharmacy as a threat is bracing for the wrong collision. The collision that matters is the hemp wall coming down and a wave of orphaned demand washing toward the licensed shelf.
So position for it. Build production that scales the day that wave arrives. Win on quality and experience, not on a regulatory loophole that is closing anyway. And keep one eye on the pharmaceutical rail, because the two economies will touch eventually, and the operators who saw it coming will be standing at the junction when they do.
The machine was built long before the rescheduling order arrived. The order only switched on the lights. The operators still arguing about rescheduling are staring at the switch. The ones who win the next cycle are already studying the machine.
Flavor chemist and microbiologist James Stephens is co-founder of Sinful, a cannabis beverage platform focused on translating modern food and beverage science into repeatable, scalable THC experiences. Previously, he founded Blue Marble, a fermentation company that produced natural flavor and fragrance ingredients.
